Literature DB >> 6705421

Rationale for monitoring free drug levels.

R H Levy, T A Moreland.   

Abstract

Recent developments in our knowledge of drug binding prompt the questions, in what circumstances are measurements of free levels necessary, desirable or not warranted? Free level monitoring should be considered for drugs for which the usefulness of plasma level monitoring has been established, drugs which are highly bound to plasma proteins, and which exhibit a variable free fraction. In terms of drug distribution, free drug concentration is independent of free fraction, while total concentration is a resultant of free concentration and free fraction. For drugs with a low extraction ratio, the total concentration at steady-state depends upon free fraction, but the free concentration is independent of free fraction. With high extraction ratio drugs, the free concentration is dependent upon free fraction but only after parenteral administration. There are numerous examples of drugs which are highly bound and exhibit large variations in free fraction. Free fraction may increase with drug concentration. Pathophysiological changes in the binding ligands, albumin and alpha 1-acid glycoprotein, as well as changes in the concentration of endogenous compounds which compete for binding sites, may also cause changes in free drug fraction. Binding interactions resulting from polytherapy may also result in a variable free fraction. Ultrafiltration devices now enable the convenient and accurate determination of free drug levels. Areas in which this should prove useful are investigations of concentration-effect relationships and clinical situations requiring intensive monitoring where binding changes are suspected.

Mesh:

Substances:

Year:  1984        PMID: 6705421     DOI: 10.2165/00003088-198400091-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  3 in total

1.  Errors in interpretation of data from equilibrium dialysis protein binding experiments.

Authors:  H L Behm; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-10

2.  High unbound fraction of salicylate in plasma during intoxication.

Authors:  G Alván; U Bergman; L L Gustafsson
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

3.  Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum.

Authors:  F Albani; R Riva; G Procaccianti; A Baruzzi; E Perucca
Journal:  Epilepsia       Date:  1983-02       Impact factor: 5.864

  3 in total
  14 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.

Authors:  G J Johnson; C J Kilpatrick; R W Bury; R O Fullinfaw; R F Moulds
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

Review 5.  The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.

Authors:  D K Meijer; P Van der Sluijs
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

6.  Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.

Authors:  M N Dudley; W C Shyu; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 7.  Effects of ethanol on drug and metabolite pharmacokinetics.

Authors:  E A Lane; S Guthrie; M Linnoila
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

8.  Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

Authors:  K Turnheim
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Audit of a monitoring service for free phenytoin.

Authors:  G M Peterson; S McLean; R J von Witt; K S Millingen
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

10.  In vitro protein binding of propafenone in normal and uraemic human sera.

Authors:  G L Chan; J E Axelson; J D Price; K M McErlane; C R Kerr
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.